Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.48 |
| ▸ | CA12 | O43570 | 5/20 | 0.45 |
| ▸ | CA9 | Q16790 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MME | P08473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12913872 | 0.77 | CA14 (0.50) | CA14CA12CA9CA1CA2 | |
| SCHEMBL17451870 | 0.77 | CA14 (0.50) | CA14CA12CA9CA1CA2 | |
| SCHEMBL8376397 | 0.77 | CA14 (0.44) | CA14CA12CA9CA1CA2 | |
| SCHEMBL6076619 | 0.76 | ALDH1A1 (0.40) | CA12CA9CA1CA2ALDH1A1 | |
| SCHEMBL9125708 | 0.76 | CA12 (0.47) | CA14CA12CA9CA1CA2 | |
| SCHEMBL8376394 | 0.75 | CA14 (0.43) | CA14CA12CA9CA1CA2 | |
| SCHEMBL15912190 | 0.75 | CA14 (0.48) | CA14CA12CA9CA1CA2 | |
| SCHEMBL399617 | 0.70 | — | — | |
| SCHEMBL10885860 | 0.70 | — | — | |
| SCHEMBL4904213 | 0.70 | CA14 (0.43) | CA14CA12CA9CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260098029-A1 | KIF18A INHIBITORS | AMGEN INC. (US) | 2026-04-09 | — | — | US | disclosed |
| US-20240317715-A1 | KIF18A INHIBITORS | AMGEN INC. (US) | 2024-09-26 | — | — | US | disclosed |
| US-12091425-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2024-09-17 | — | — | US | disclosed |
| US-12054476-B2 | KIF18A inhibitors | AMGEN INC. (US) | 2024-08-06 | — | — | US | disclosed |
| US-20230052348-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2023-02-16 | — | — | US | disclosed |
| US-11306107-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2022-04-19 | — | — | US | disclosed |
| US-20220106293-A1 | KIF18A INHIBITORS | AMGEN INC. (US) | 2022-04-07 | — | — | US | disclosed |
| US-11286235-B2 | Ultra short acting anti-arrhythmic agents | Academic Pharmaceuticals, Incorporated (US) | 2022-03-29 | — | — | US | disclosed |
| US-11236069-B2 | KIF18A inhibitors | AMGEN INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-11236069-B2 | KIF18A inhibitors | AMGEN INC. (US) | 2022-02-01 | — | — | US | disclosed |
| EP-1334088-A1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 AND NK-2 RECEPTOR ANTAGONISTS | GlaxoSmithKline S.p.A. (IT) | 2003-08-13 | — | — | EP | disclosed |
| WO-2002038548-A1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 AND NK-2 RECEPTOR ANTAGONISTS | GLAXOSMITHKLINE S.P.A. (IT) | 2002-05-16 | — | — | WO | disclosed |
| EP-0713093-B1 | Improved methodology for colorimetrically determining the concentration of white blood cells in a biological fluid | BAYER AG (US) | 2001-10-10 | — | — | EP | disclosed |
| US-6114532-A | ANTICOAGULANT | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2000-09-05 | — | — | US | disclosed |
| EP-0698600-B1 | Composition, method and test device for determining the presence of leukocyte cells, esterase or protease in a test sample | BAYER AG (US) | 1999-11-10 | — | — | EP | disclosed |
| US-5663044-A | Methodology for colorimetrically determining the concentration of white blood cells in a biological fluid | BAYER CORPORATION (US) | 1997-09-02 | — | — | US | disclosed |
| EP-0713093-A2 | Improved methodology for colorimetrically determining the concentration of white blood cells in a biological fluid | Bayer Corporation (US) | 1996-05-22 | — | — | EP | disclosed |
| US-5512450-A | TEST PAD COMPRISING CARRIER MATRIX WITH HOMOGENEOUSLY INCORPORATED REAGENT INCLUDING HYDROXY-BLOCKED LACTATE ESTER WHICH GENERATES COMPOUND PROVIDING DETECTABLE RESPONSE WHEN HYDROLYZED, BUFFER | BAYER CORPORATION (US) | 1996-04-30 | — | — | US | disclosed |
| EP-0698600-A1 | Composition, method and test device for determining the presence of leukocyte cells, esterase or protease in a test sample | Bayer Corporation (US) | 1996-02-28 | — | — | EP | disclosed |
| US-5464739-A | Urinalysis, hydrolysis of lactate ester | BAYER CORPORATION (US) | 1995-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317715-A1 | KIF18A INHIBITORS | KIF18A, KIF18B, KIF15 | CA14 3820/4885CA12 3970/4885CA9 2898/4885 |
| US-11306107-B2 | Compounds that inhibit MCL-1 protein | MCL1, BCL9, BCL2L1 | CA14 4844/4885CA12 4825/4885CA9 4744/4885 |
| US-20220106293-A1 | KIF18A INHIBITORS | KIF18A, KIF18B, KIF15 | CA14 3820/4885CA12 3970/4885CA9 2898/4885 |
| US-12054476-B2 | KIF18A inhibitors | KIF18A, KIF18B, KIF15 | CA14 3820/4885CA12 3970/4885CA9 2898/4885 |
| US-20260098029-A1 | KIF18A INHIBITORS | KIF18A, KIF18B, KIFC1 | CA14 2263/4885CA12 2898/4885CA9 1467/4885 |
| US-11236069-B2 | KIF18A inhibitors | KIF18A, KIF18B, KIF15 | CA14 3820/4885CA12 3970/4885CA9 2898/4885 |
| US-11286235-B2 | Ultra short acting anti-arrhythmic agents | SCN5A, CACNA1G, CACNA1H | CA14 4865/4885CA12 4821/4885CA9 4795/4885 |
| US-20230052348-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | MCL1, BCL9, BCL2L1 | CA14 4844/4885CA12 4825/4885CA9 4744/4885 |
| US-12091425-B2 | Compounds that inhibit MCL-1 protein | MCL1, BCL9, BCL2L1 | CA14 4844/4885CA12 4825/4885CA9 4744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.